parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in alveolar cells type 1	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 25	0.85
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 12969

ATP13A4 in dopamine neurons, braak+0.47 (p 0.202) → +0.22 (p 0.565)receipt 12977
ATP13A4 in astrocytes, braak+0.45 (p 0.219) → -0.42 (p 0.255)receipt 12976

receipt 12977: ATP13A4 in dopamine neurons, braak

power: full sample +0.45 (p 0.063, n 18), 95% CI -0.03 to +0.76. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.42 (p 0.086, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.38 (p 0.116, n 18). could be the mix.
skeptic: leave-one-out range +0.37 to +0.60, sign flips 0; without severely affected donors +0.45 (p 0.063, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ATP13A4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12976: ATP13A4 in astrocytes, braak

power: full sample +0.01 (p 0.969, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.10 (p 0.683, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.21 (p 0.403, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.13, sign flips 6; without severely affected donors +0.01 (p 0.969, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ATP13A4 in astrocytes.

case closed: nothing better to follow up.

loading the receipts